Drugs and Devices

FDA approves drug to reduce CV deaths in patients with diabetes

On Dec. 2, the Food and Drug Administration (FDA) approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and cardiovascular disease. Read more

Related Articles:

Leave a Reply

You have to agree to the comment policy.


Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing